BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)

Rudolph M Navari,Erminio Bonizzoni,Rita Wickham,Rebecca Clark-Snow

doi:10.6004/jnccn.2019.7430

BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)

Rudolph M Navari, Erminio Bonizzoni + Show 2 more

https://doi.org/10.6004/jnccn.2019.7430

Copy DOI

Journal: Journal of the National Comprehensive Cancer Network	Publication Date: Mar 20, 2020
Citations: 1

Affiliation: University of Milan, Australian College of Nursing, Hematology Oncology Consultants, University of Alabama at Birmingham

#Netupitant / Palonosetron #Chemotherapy-Induced Nausea And Vomiting + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)

Full Text